SOMERSET, N.J., Aug. 4, 2010 (GLOBE NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV) ("inVentiv"), a leading provider of end-to-end clinical development, launch and commercialization services to the global pharmaceutical and healthcare industries, today announced the completion of the transaction providing for the acquisition of inVentiv Health, Inc. by inVentiv Group Holdings, Inc. (formerly Papillon Holdings, Inc.), an entity created and funded by certain affiliates of Thomas H. Lee Partners, L.P. ("THL"), Liberty Lane Partners, LLP ("Liberty Lane"), certain co-investors and members of the inVentiv management team. Pursuant to the terms of the merger agreement, inVentiv shareholders will receive $26.05 in cash for each share of VTIV common stock they hold. As a result of the merger, inVentiv's common stock will no longer be listed on NASDAQ. Stockholders of record will receive a letter of transmittal and instructions on how to surrender their shares of inVentiv common stock in exchange for the merger consideration. Stockholders of record should wait to receive the letter of transmittal before surrendering their shares. About inVentiv Health inVentiv Health, Inc. is a leading provider of value-added, outsourced services to the pharmaceutical, life sciences and healthcare industries. inVentiv provides a broad range of clinical development, communications and commercialization services that are critical to its clients' ability to successfully develop, launch and commercialize pharmaceutical products and medical devices. inVentiv serves its clients across all phases of the product lifecycle by providing a full suite of outsourced services in each of its operational areas on a flexible and cost-effective basis. inVentiv delivers services to more than 350 leading pharmaceutical, biotech, life sciences and healthcare payer companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com . The inVentiv Health, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4942 About Thomas H. Lee Partners, L.P.